25. February 2016

Curious about your antibody or anti-serum?



PEPperPRINT and Zedira commonly present the new PEPperCHIP® Transglutaminase Microarray!

The PEPperCHIP® Transglutaminase Microarray is based on 6 transglutaminase variants (hFXIII, hTG1, hTG2, hTG3, hTG4 and hTG6) and can be used for

high resolution epitope mapping of anti-transglutaminase antibodies
antibody specificity analysis with 6 different transglutaminase antigens
serum antibody screening for anti-transglutaminase antibodies
isotype-specific IgG and IgA profiling from serum and plasma
   correlation of anti-transglutaminase antibody responses with pathogenesis

Art. No.    Name    Unit    Price
P111      PEPperCHIP® Transglutaminase Microarray
(Standard microarray)		      1 Chip      425 €
P112   PEPperCHIP® Custom Transglutaminase Microarray
(Customized transglutaminase microarray layout)		   1 Chip   895 €
P113   PEPperCHIP® Transglutaminase Microarray Service
(Full service IgG and IgA analysis of one sample)		   1 Sample   695 €

   Learn more about PEPperCHIP® Laser Printing Platform or
Learn more about PEPperCHIP® Epitope Mapping


Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.
    All products

News  

  • imagePreview: Catalogue Editorial 2019
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
    Read more All news
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
    Read more All news
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
    Read more All news
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
    Read more All news
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
    Read more All news
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
    Read more All news
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
    Read more All news
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
    Read more All news
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
    Read more All news
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
    Read more All news
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
    Read more All news
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation
    Read more All news

Blog  

Events  

  • Life Sciences 2019: Post-translational modifications and cell signalling

    17.03.2019 - 18.03.2019
    Nottingham, UK

    All events
  • 10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)

    16.05.2019 - 17.05.2019
    Sheffield, UK

    All events
  • 27th ISTH Congress

    06.06.2019 - 10.06.2019
    Melbourne, Australia

    All events
  • 18th International Celiac Disease Symposium ICDS

    04.09.2019 - 07.09.2019
    Paris, France

    All events
  • Workshop on Transglutaminase Research

    28.09.2019 - 01.10.2019
    Marrakech, Morocco

    All events